Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
Wk 12/14
Company Bank Analyst Coverage Opinion chg cls
Acadia (ACAD) JMP Securities Charles Duncan Upgrade Strong buy (from market outperform) -3% $12.03
Duncan upgraded the stock after top-line Phase II data for pimavanserin to treat schizophrenia confirmed the compound's previously reported improvement in antipsychotic efficacy.
Advanced Life (ADLS) Rodman Elemer Piros Price target Market outperform -12% $1.71
Piros lowered his target to $5 from $6 after ADLS raised $19.4M on Dec. 11 through the sale of 10.2M shares at $1.90. He said the price was lower than he expected, which resulted in more dilution (see B37).
Alexion (ALXN) Banc of America Securities William Sargent Price target Buy -1% $74.38
Sargent raised his target to

Read the full 1248 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers